ClinicalTrials.gg
CompletedNCT06571266Updated May 16, 2025

A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants

A Phase 1 interventional study of Risankizumab in Healthy Volunteers, sponsored by AbbVie. Completed at 3 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study will assess the pharmacokinetics, relative bioavailability and tolerability of two formulations of risankizumab following subcutaneous (SC) administration in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
  • Risankizumab
  • ABBV-066
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight 40 kg to 100 kg, inclusive, at screening and upon initial confinement
  • (BMI) is > = 18.0 to \< = 32.0 kg/m2 after rounded to the tenths decimal, at Screening and upon confinement.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead .

Exclusion criteria

Exclusion Criteria:

  • Participant with exposure to any anti-interleukin-12/23 or anti-interleukin-23 treatment for at least one year prior to Screening.
  • Participant with intention to perform strenuous exercise within at least one week prior to administration of study drug or during the study.
  • History of epilepsy, any cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
231 participants (actual)

Study arms

  • Experimental
    Risankizumab Formulation 1

    Participants will receive a single dose of Risankizumab formulation 1 on day 1.

    Drug: Risankizumab

  • Experimental
    Risankizumab Formulation 2

    Participants will receive a single dose of Risankizumab formulation 2 on day 1.

    Drug: Risankizumab

  • Experimental
    Risankizumab Formulation 3

    Participants will receive a single dose of Risankizumab formulation 3 on day 1.

    Drug: Risankizumab

Interventions

  • • Subcutaneous Injection via prefilled syringe

    Also known as: ABBV-066, SKYRIZI

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to day 140

  2. Maximum Observed Serum Concentration (Cmax) of Risankizumab

    Cmax will be assessed of Risankizumab

    Time frame: Up to Day 140

  3. Time to Cmax (Tmax) of Risankizumab

    Tmax will be assessed of Risankizumab

    Time frame: Up to Day 140

  4. Apparent Terminal Phase Elimination Rate Constant (β) of Risankizumab

    Apparent terminal phase elimination rate constant (β) will be assessed of Risankizumab

    Time frame: Up to Day 140

  5. Terminal Phase Elimination Half-life (t1/2) of Risankizumab

    Terminal phase elimination half-life (t1/2) will be assessed of Risankizumab

    Time frame: Up to Day 140

  6. Area Under the Concentration-time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUC0-t)

    AUC0-t will be assessed

    Time frame: Up to Day 140

  7. AUC from Time 0 to Infinity (AUC0-inf) of Risankizumab

    AUC0-inf will be assessed of Risankizumab

    Time frame: Up to Day 140

  8. Number of Anti-drug antibody (ADA) Titers

    Incidence and concentration of anti-drug antibodies

    Time frame: Up to Day 140

07

Study locations

3 sites
  • Cenexel Act /ID# 270310
    Anaheim, California 92801, United States
  • Collaborative Neuroscience Research CNS /ID# 270286
    Los Alamitos, California 90720, United States
  • Acpru /Id# 270152
    Grayslake, Illinois 60030, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Apr 2025, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2024
First posted
Aug 26, 2024
StartActual
Sep 11, 2024
Primary completionActual
Apr 16, 2025
CompletionActual
Apr 16, 2025
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06571266
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Sep 11, 2024
Primary completion
Apr 16, 2025
Completion
Apr 16, 2025
Last update
May 16, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion